An interventional study of Protein powder intervention and Resistance exercise intervention in Sarcopenia, sponsored by Weiwei Ma. Not yet recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Weiwei Ma · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.
Among the 83 studies in Sarcopenia with a site in China, this one is the 10th largest by planned enrollment of the 52 interventional ones that give a count, is one of 11 that started in 2025, is one of 42 with no phase, reaches primary completion later than 21 of the 51 other live ones, and was the 55th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:
Shanghai Yueyang Integrated Medicine Hospital · Sites in China
Ages 60–90
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 60+
GuangZhou Cellgenes Biotechnology Co., Ltd. · Sites in China
Ages 50–85
Peking Union Medical College Hospital · Sites in China
Ages 18+
China Medical University, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2012; this study’s year is marked. 11 started in 2025.
This study's planned enrollment of 224 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 110 across the 52 interventional studies, 868 across the 31 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 83 have an industry lead sponsor. The 10 most frequent:
Weiwei Ma is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Weiwei Ma has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
14 of the studies in Sarcopenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07950150The Hong Kong Polytechnic UniversityPomegranate-Prebiotic Supplementation for Sarcopenic Obesity | 2026-12 |
| NCT07049731Weiwei MaImprovement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise | 2026-12 |
| NCT07724587Ningbo Medical Center Lihuili HospitalThe Effectiveness and Safety of Combined Research on Uremic Sarcopenia | 2026-12-01 |
| NCT07059871Zhejiang HospitalA Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. | 2026-12-30 |
| NCT07538674Shanghai Yueyang Integrated Medicine HospitalPeiyuan Guben Tongluo Ointment for Elderly Sarcopenia | 2027-03-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 83 studies in Sarcopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is an age-related progressive skeletal muscle disease, the prevalence of which is increasing year by year with the aging of China's population, seriously affecting the health and quality of life of the elderly. Relevant studies have shown that protein intake in combination with resistance exercise can significantly improve muscle mass and function, and the effect is superior to that of a single intervention. In addition, ingredients such as vitamin D, N-acetylglucosamine, sodium hyaluronate, and taurine can further promote muscle health by regulating metabolism and inflammation levels. However, there are relatively few intervention studies combining the above nutrients with resistance exercise in patients with sarcopenia. Therefore, this study intends to use protein powder containing milk protein, vitamin D, N-acetylglucosamine, sodium hyaluronate, taurine and other ingredients, combined with low-intensity resistance exercise, to intervene in the middle-aged and elderly patients with sarcopenia, and to explore and observe the effects on muscle mass, bone density, intestinal health and other indexes of patients with sarcopenia, with the aim of providing a more accurate nutritional and exercise intervention program for the prevention and treatment of sarcopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the diagnostic criteria for sarcopenia AWGS 2019
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Placebo control
Dietary Supplement: Protein powder intervention
Behavioral: Resistance exercise intervention · Dietary Supplement: Placebo control
Dietary Supplement: Protein powder intervention · Behavioral: Resistance exercise intervention
On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
Low-intensity resistance training was conducted 3 times a week.
placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
Extremity Skeletal Muscle Mass Index (ASMI)
ASM was measured using BIA, ASMI=ASM/height (m)\^2.
Time frame: Baseline, month 3, month 6
Handgrip strength
Maximum force grip was held for 3 seconds, the right and left hands were measured alternately, 3 measurements were taken in each hand, and the maximum value was taken.
Time frame: Baseline, month 3, month 6
6m walking speed
Let the tester start from the starting point, walk 6 meters at normal walking speed, stop when reaching the end point, record the time used, and calculate the 6m walking speed according to the time used and the distance of 6 meters.
Time frame: Baseline, month 3, month 6
Chair sitting and standing test
The subject sat in the center of the chair, crossed his/her arms in front of his/her chest, and after hearing the command "start", he/she completed 5 consecutive times of standing up and sitting down, and recorded the total time in seconds.
Time frame: Baseline, month 3, month 6
Simple Physical Performance Battery (SPPB)
The SPPB consists of 3 test items, each item is scored out of 4 points, and the total score is 12.
Time frame: Baseline, month 3, month 6
General survey
Using a questionnaire designed by the research team and validated by the previous study, the survey covered the age, gender, ethnicity, marital status, occupation, education level, place of residence, household income, living status (living alone and with family), dietary habits and application of nutritional supplements, lifestyle (smoking, drinking, and physical activity), family history, and chronic diseases (hypertension, diabetes, etc.) of the study participants, Hyperlipidemia, etc.)
Time frame: Baseline, month 6
Height
Measure the height of the subjects
Time frame: Baseline, month 3, month 6
Weight
Measure the weight of the subjects
Time frame: Baseline, month 3, month 6
Body Mass Index(BMI)
Calculate BMI using height and weight , BMI=weight/(height)\^2
Time frame: Baseline, month 6
Waist circumference, hip circumference, and waist to hip ratio
Measure the waist and hip circumference of the subjects and calculate the waist to hip ratio (waist circumference/hip circumference).
Time frame: Baseline, month 3, month 6
Body composition
Using a human body composition analyzer to detect indicators such as total score, visceral fat area, body segment fat and basal metabolic rate, body cell mass, and limb skeletal muscle mass index.
Time frame: Baseline, month 6
Assessment of ability to perform activities of daily living
The ADL was assessed using the Activity of Daily Living Scale (ADL), which consists of 10 items, including eating, bathing, grooming, dressing, bowel control, urination control, toileting, bed and chair transfers, walking, and walking up and down stairs. The total score is 100, with a score of more than 60 indicating mild functional impairment but basic self-care in daily life; a score of 60-41 indicating moderate functional impairment and need for some assistance in daily life; a score of 40-21 indicating severe functional impairment and obvious need for dependence on others in daily life; and a score of less than 20 indicating complete disability and total dependence on others in daily life.
Time frame: Baseline, month 3, month 6
Sleep assessment
The PSQI (Pittsburgh Sleep Quality Index) questionnaire was used to assess the quality of the subjects' sleep during the last 1 month. It consists of 19 self-assessment and 5 other-assessment entries, of which the 19th self-assessment and 5 other-assessment entries are not involved in scoring. The cumulative score of each component is the total PSQI score, which ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Time frame: Baseline, month 3, month 6
Analysis of dietary intake
The 3-day, 24-hour dietary recall method was used to investigate the subjects' dietary intake. The survey process was supplemented with tools such as the "Retrospective Dietary Survey Auxiliary Chart" to help the subjects accurately recall their dietary intake. Based on the Standardized Version of the Chinese Food Composition Table (6th Edition), the energy and various types of protein, fat and carbohydrate intake of the population were calculated, and for the missing data in the Chinese Food Composition Table, the United States Department of Agriculture Food Composition Table was used to supplement the data, so as to build up a comprehensive database of dietary intake. The analysis of dietary intake included the intake of total fat, total protein, total carbohydrates and energy and its percentage in the total energy intake.
Time frame: Baseline, month 6
Assessment of overall cognitive functioning
Subjects were assessed for overall cognitive functioning using the Montreal cognitive assessment (MoCA) scale out of 30, which contains cognitive functioning tests in multiple dimensions of visuospatial and executive functioning, naming, memory, attention, language, abstraction, delayed recall, and orientation.The normal threshold is usually ≥ 26 points, 21-25 points indicate mild cognitive impairment, and ≤ 20 points may indicate dementia risk
Time frame: Baseline, month 6
Bone density
Bone density, lumbar spine bone density (lumbar 2 - lumbar 4) and left femoral neck bone density are examined using the dualenergy X-ray absorptiometry (DXA) method.
Time frame: Baseline, month 6
Knee joint ultrasound
Ultrasound was used to examine the knee joint cavity for fluid or synovial hyperplasia and the tendon ligaments and muscles around the knee joint for damage.
Time frame: Baseline, month 6
Knee injury and osteoarthritis outcome score (KOOS score)
The KOOS rating includes five independent evaluation dimensions, each calculated separately and converted into a percentage scale (0-100 points, with higher scores indicating better functionality)
Time frame: Baseline, month 3, month 6
Serum sarcopenia related factors
Detect serum calcium (Ca), phosphorus (P), serum hydroxyvitamin D (25(OH)D), serum parathyroid hormone (PTH), P-alkaline phosphatase (ALP), serum osteocalcin (OC), serum type 1 pro-collagen N-terminal pre-peptide, serum type 1 collagen cross-linking N-terminal peptide (NTX), and serum anti-tartrate acid phosphatase 5b (TRACP-5b), estradiol (E2), leptin (LP), and so on.
Time frame: Baseline, month 6
Blood lipid concentration
Determine the serum levels of blood lipid concentration in the population. Lipid tests include total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).
Time frame: Baseline, month 6
Blood glucose concentration
Blood glucose tests are fasting blood glucose.
Time frame: Baseline, month 6
Insulin concentration
Measurement of insulin secretion level.
Time frame: Baseline, month 6
Inflammation-related biochemical indicators
Detecting inflammatory cytokine concentration: including TNF-α, IL-1 α, IL-1 β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10 and other inflammatory factors.
Time frame: month 6
Detection of intestinal flora species, quantity and differentiation level in human population
The collected feces were subjected to 16S rRNA sequencing technology to detect the diversity of gut microbiota.
Time frame: month 6
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 16 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weiwei Ma